Revlimid Perks Celgene’s First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Bottom line takes an expected hit with Pharmion buyout.
You may also be interested in...
Celgene Withdraws EU Filing For Revlimid After Second CHMP Refusal
Company counters setback by unveiling promising lenalidomide data from NHL, newly diagnosed multiple myeloma trials during ASCO.
Celgene Withdraws EU Filing For Revlimid After Second CHMP Refusal
Company counters setback by unveiling promising lenalidomide data from NHL, newly diagnosed multiple myeloma trials during ASCO.
ASCO Early Release Offers Highlights, But The Best Is Yet To Come
Part one of “The Pink Sheet” DAILY’s review of roughly 5,000 abstracts released ahead of the American Society of Clinical Oncology annual meeting.